Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Apr 16 · above the Ichimoku cloud · RSI 62 · MACD above its signal · 3% below its 52-week high
None of the 29 investors followed here reported a position in GLAND.NS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GLAND.NS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.2 | -1.3 | -6.9 | 3.2 | 28.5 | 10.9 | 0.3 | 15.3 | 0.5 | 5.3 | +77.3% | ||
| 2025 | -14.3 | 1.8 | 2.6 | -12.1 | 13.5 | 15.4 | 12.6 | -9.4 | 6.4 | -3.1 | -8.8 | -2.1 | −3.2% |
| 2024 | 1.7 | -9.7 | 4.5 | -7.3 | 7.5 | -0.8 | 17.4 | -14.2 | -2.3 | -8.1 | 5.3 | 2.4 | −7.5% |
| 2023 | -17.5 | 1.3 | -3.8 | 7.1 | -32.0 | 15.0 | 23.1 | 33.2 | -3.8 | -7.7 | 14.8 | 8.4 | +22.1% |
| 2022 | -11.3 | -4.8 | 0.3 | -2.2 | -10.6 | -5.6 | -16.3 | 4.8 | -11.6 | -14.7 | -0.3 | -11.4 | −59.2% |
| 2021 | -9.6 | 13.5 | 3.2 | 12.2 | 13.4 | 8.6 | 14.8 | -0.9 | -4.5 | -0.5 | -3.1 | 7.8 | +65.2% |
| 2020 | 10.7 | +10.7% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 12, 2026 | Mirae Asset Emerging Bluechip FundInstitution- Corporation | — | 3.35M | — |
| May 31, 2026 | Jayatheertha (A)UNREPORTED | Sale at price 24.79 per share. | 1K | $24.79K |
| May 26, 2026 | Rao (Raghuramachandra K)UNREPORTED | Sale at price 24.24 per share. | 1K | $24.24K |
| May 24, 2026 | Rao (Raghuramachandra K)UNREPORTED | Sale at price 24.63 per share. | 1K | $24.63K |
| May 20, 2026 | Rao (Srinivasa S)UNREPORTED | Sale at price 23.91 per share. | 500 | $11.95K |
| May 20, 2026 | Jayatheertha (A)UNREPORTED | Sale at price 24.48 per share. | 500 | $12.24K |
| May 18, 2026 | Jayatheertha (A)UNREPORTED | Sale at price 23.18 per share. | 346 | $8.02K |
| May 18, 2026 | Jayatheertha (A)UNREPORTED | Sale at price 23.15 per share. | 1K | $23.15K |
| May 17, 2026 | Rao (Srinivasa S)UNREPORTED | Sale at price 22.52 per share. | 1K | $22.52K |
| Feb 8, 2026 | Jayatheertha (A)UNREPORTED | Sale at price 20.81 per share. | 100 | $2.08K |
| Feb 1, 2026 | Jayatheertha (A)UNREPORTED | Sale at price 21.06 per share. | 306 | $6.44K |
| Feb 1, 2026 | Pulaparthi (Lakshmi Narayana)UNREPORTED | Sale at price 20.39 per share. | 800 | $16.31K |
| Nov 20, 2025 | Pulaparthi (Lakshmi Narayana)Promoter | Sale at price 20.12 per share. | 300 | $6.04K |
| Sep 25, 2025 | Jayatheertha (A)UNREPORTED | Sale at price 22.43 per share. | 191 | $4.28K |
| Sep 22, 2025 | Jayatheertha (A)UNREPORTED | Sale at price 22.95 per share. | 325 | $7.46K |
| Apr 10, 2025 | Icici Prudential Emerging Star FundInstitution- Corporation | — | 400K | — |
| Feb 25, 2025 | Rao (Srinivasa S)UNREPORTED | Other at price 6.22 per share. | 2.8K | $17.42K |
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, and neurological and central nervous system; blood related, ophthalmics and otologicals, cardiac, gastro-intestinal, and hormonal products; pain, neuromuscular blocking agents, and analgesics; respiratory and pulmonology; and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier preparation, and technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Buy / hold / sell counts
No recent headlines.